145 related articles for article (PubMed ID: 24113146)
1. What place for lisdexamfetamine in children and adolescents with ADHD?
Drug Ther Bull; 2013 Oct; 51(10):114-7. PubMed ID: 24113146
[TBL] [Abstract][Full Text] [Related]
2. Lisdexamfetamine Dimesylate: A Review in Paediatric ADHD.
Frampton JE
Drugs; 2018 Jul; 78(10):1025-1036. PubMed ID: 29923015
[TBL] [Abstract][Full Text] [Related]
3. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006.
Harpin VA
Arch Dis Child Educ Pract Ed; 2008 Apr; 93(2):58-65. PubMed ID: 18356307
[TBL] [Abstract][Full Text] [Related]
4. Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder.
Steer C; Froelich J; Soutullo CA; Johnson M; Shaw M
CNS Drugs; 2012 Aug; 26(8):691-705. PubMed ID: 22762726
[TBL] [Abstract][Full Text] [Related]
5. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.
Wong IC; Asherson P; Bilbow A; Clifford S; Coghill D; DeSoysa R; Hollis C; McCarthy S; Murray M; Planner C; Potts L; Sayal K; Taylor E
Health Technol Assess; 2009 Oct; 13(50):iii-iv, ix-xi, 1-120. PubMed ID: 19883527
[TBL] [Abstract][Full Text] [Related]
6. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
[TBL] [Abstract][Full Text] [Related]
7. Parent-reported executive function behaviors and clinician ratings of attention-deficit/hyperactivity disorder symptoms in children treated with lisdexamfetamine dimesylate.
Findling RL; Adeyi B; Dirks B; Babcock T; Scheckner B; Lasser R; DeLeon A; Ginsberg LD
J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):28-35. PubMed ID: 23410139
[TBL] [Abstract][Full Text] [Related]
8. Lisdexamfetamine: a prodrug for the treatment of attention-deficit/hyperactivity disorder.
Popovic B; Bhattacharya P; Sivaswamy L
Am J Health Syst Pharm; 2009 Nov; 66(22):2005-12. PubMed ID: 19890083
[TBL] [Abstract][Full Text] [Related]
9. [Lisdexamfetamine dimesylate: a Treatment Option for Children and Adolescents with Attention Deficit/Hyperactivity Disorder in Germany and Across Europe].
Häge A; Banaschewski T; Dittmann RW
Fortschr Neurol Psychiatr; 2015 Dec; 83(12):676-85. PubMed ID: 26714249
[TBL] [Abstract][Full Text] [Related]
10. Trends in attention-deficit and hyperactivity disorder (ADHD) medications among children and young adults in Ireland: a repeated cross-sectional study from 2005 to 2015.
Mac Avin M; Teeling M; Bennett KE
BMJ Open; 2020 Apr; 10(4):e035716. PubMed ID: 32327478
[TBL] [Abstract][Full Text] [Related]
11. The use of lisdexamfetamine dimesylate for the treatment of ADHD.
Childress AC; Sallee FR
Expert Rev Neurother; 2012 Jan; 12(1):13-26. PubMed ID: 22243042
[TBL] [Abstract][Full Text] [Related]
12. The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care.
McCarthy S; Wilton L; Murray ML; Hodgkins P; Asherson P; Wong IC
BMC Pediatr; 2012 Jun; 12():78. PubMed ID: 22712630
[TBL] [Abstract][Full Text] [Related]
13. Lisdexamfetamine.
Blick SK; Keating GM
Paediatr Drugs; 2007; 9(2):129-35; discussion 136-8. PubMed ID: 17407369
[TBL] [Abstract][Full Text] [Related]
14. Prediction of placebo response in 2 clinical trials of lisdexamfetamine dimesylate for the treatment of ADHD.
Waxmonsky JG; Waschbusch DA; Glatt SJ; Faraone SV
J Clin Psychiatry; 2011 Oct; 72(10):1366-75. PubMed ID: 21367347
[TBL] [Abstract][Full Text] [Related]
15. An update on lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder.
Wigal SB; Raja P; Shukla A
Expert Opin Pharmacother; 2013 Jan; 14(1):137-45. PubMed ID: 23241144
[TBL] [Abstract][Full Text] [Related]
16. Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications.
Setyawan J; Guérin A; Hodgkins P; Gauthier G; Cloutier M; Wu E; Erder MH
J Med Econ; 2013 Nov; 16(11):1275-89. PubMed ID: 24004347
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
Najib J
Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
[TBL] [Abstract][Full Text] [Related]
18. Lisdexamfetamine dimesylate: in attention-deficit hyperactivity disorder in adults.
Weber J; Siddiqui MA
CNS Drugs; 2009; 23(5):419-25. PubMed ID: 19453202
[TBL] [Abstract][Full Text] [Related]
19. [Update on Current Care guidelines: ADHD (attention-deficit/hyperactivity disorder, children and adolescents)].
Käypä hoito suosituksen päivitystiivistelmä
Duodecim; 2012; 128(5):539-40. PubMed ID: 22486070
[TBL] [Abstract][Full Text] [Related]
20. Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.
Wigal SB; Chae S; Patel A; Steinberg-Epstein R
Semin Pediatr Neurol; 2010 Dec; 17(4):230-6. PubMed ID: 21183129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
